We’re not just removing the needle.
We’re removing the barrier to better care.
We’re not just removing the needle. We’re removing the barrier to better care.
MOGLU®
Final version: 40 x 30 x 16 mm
MOGLU®
Final version: 40 x 30 x 16 mm
MOGLU®
Final version: 40 x 30 x 16 mm
MOGLU®
Final version: 40 x 30 x 16 mm
IRB-approved trials at MIT showed performance on par with top CGMs ― without needles.

Consistency of Readings
A low MARD (mean absolute relative difference)
can be misleading without tight data clustering—
consistency matters more than a single number
Consistency of Readings
A low MARD (mean absolute relative difference) can be misleading without tight data clustering—consistency matters more than a single number.
100% in the Clinical Validated Zone
In Clarke Error Grid analysis,
all 279 data points fell within Zone A or B.
100% in the Clinical Validated Zone
In Clarke Error Grid analysis, all 279 data points fell within Zone A or B.
MOGLU®
Final version: 40 x 30 x 16 mm
Consistency of Readings
A low MARD (mean absolute relative difference) can be misleading without tight data clustering—consistency matters more than a single number
Consistency of Readings
A low MARD (mean absolute relative difference) can be misleading without tight data clustering—consistency matters more than a single number
100% in the Clinical Validated Zone
In Clarke Error Grid analysis, all 279 data points fell within Zone A or B.
100% in the Clinical Validated Zone
In Clarke Error Grid analysis, all 279 data points fell within Zone A or B.
100% in the Clinical Validated Zone
In Clarke Error Grid analysis, all 279 data points fell within Zone A or B.




MOGLU® Highlights
Comfort
Needle-free means
no pain, no irritation.
Accurate
Compact
Affordable




MOGLU® Highlights
Comfort
Needle-free means
no pain, no irritation.
Accurate
Compact
Affordable




MOGLU® Highlights
Comfort
Needle-free means
no pain, no irritation.
Accurate
Compact
Affordable




Comfort
Needle-free means
no pain, no irritation.
Accurate
Compact
Affordable
MOGLU® Highlights
Technology
Technology
Technology
Reimagining diabetes care
with breakthrough Raman-based sensing.
By targeting a few key wavelengths, we enhance sensitivity
while keeping the device compact and wearable.
No full-spectrum scan required.
Backed by 50 patents.
Reimagining diabetes care
with breakthrough Raman-based sensing.
By targeting a few key wavelengths, we enhance sensitivity
while keeping the device compact and wearable.
No full-spectrum scan required.
Backed by 50 patents.
Reimagining diabetes care
with breakthrough Raman-based sensing.
By targeting a few key wavelengths, we enhance sensitivity while keeping the device compact and wearable.
No full-spectrum scan required.
Backed by 50 patents.

Our Team
Our Team
Our team
Our Team
We build needle-free continuous glucose monitors powered by Raman spectroscopy. Our teams in Boston and Seoul blend deep expertise in optics, engineering, and healthcare to deliver precision solutions for diabetes care.







Aram Hong
CEO & Co-founder

Aram Hong
CEO & Co-founder



Miyeon Jue, PhD
CTO & Co-founder

Miyeon Jue, PhD
CTO & Co-founder


Peter So, PhD
Advisor & MIT Professor

Peter So, PhD
Advisor & MIT Professor



Jeon Woong Kang, PhD
Collaborator & MIT Scientist

Jeon Woong Kang, PhD
Collaborator & MIT Scientist


Jun Ki Kim, PhD
Jun Ki Kim, PhD
Co-founder &
Asan Medical Center Professor
Co-founder &
Asan Medical Center Professor

Jun Ki Kim, PhD
Co-founder &
Asan Medical Center Professor

Jun Ki Kim, PhD
Co-founder &
Asan Medical Center Professor





Backed by
Backed by
Backed by
Backed by






























News
News
News
News
Dec 6, 2024
Korean Startup Apollon Wins CES 2025 Innovation Award for Non-Invasive Continuous Glucose Monitor
Korean Startup Apollon Wins CES 2025 Innovation Award for Non-Invasive Continuous Glucose Monitor
Korean Startup Apollon Wins CES 2025 Innovation Award for Non-Invasive Continuous Glucose Monitor
Read More
Read More
Jun 6, 2024
Korean startup Apollon lands 2.3B won investment for needle-free glucose monitoring
Korean startup Apollon lands 2.3B won investment for needle-free glucose monitoring
Korean startup Apollon lands 2.3B won investment for needle-free glucose monitoring
Read More
Read More
Aug 21, 2023
Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology
Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology
Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology
Read More
Read More
Aug 21, 2023
Apollon, MIT Collaborate on Noninvasive Glucose-Monitoring Tech
Apollon, MIT Collaborate on Noninvasive Glucose-Monitoring Tech
Apollon, MIT Collaborate on Noninvasive Glucose-Monitoring Tech
Read More
Read More
Dec 6, 2024
Korean Startup Apollon Wins CES 2025 Innovation Award for Non-Invasive Continuous Glucose Monitor
Read More
Jun 6, 2024
Korean startup Apollon lands 2.3B won investment for needle-free glucose monitoring
Read More
Aug 21, 2023
Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology